Abstract
e16527 Background: Bevacizumab (B) was FDA-approved in 2004 in combination with carboplatin and paclitaxel (CP) for treatment of first-line metastatic NSCLC after a phase III trial was conducted sh...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
